Physician profile
John Haasis
NPI 1710908496
$4,143.47
in general payments reported to CMS, 2019-2025
16 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $502 · 2021: $471 · 2022: $279 · 2023: $725 · 2024: $574 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,707.86 | 2019-2025 | Proclaim, Octrode, Eterna |
| Forte Bio-Pharma LLC | $416.19 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Nevro Corp. | $192.56 | 2022 | |
| Curonix LLC | $191.58 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Zynex Medical, INC. | $156.07 | 2025 | Nexwave |
| Biotronik Nro, INC. | $144.51 | 2025 | Prospera |
| Abbvie INC. | $105.01 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.42 | 2022-2025 | Relistor |
| Stryker Corporation | $42.44 | 2025 | |
| Collegium Pharmaceutical, INC. | $23.41 | 2025 | Belbuca |
| Stimwave Technologies Incorporated | $21.18 | 2020 | |
| Pfizer INC. | $18.16 | 2019 | |
| Hikma Pharmaceuticals USA | $15.18 | 2023 | Kloxxado |
| Astrazeneca Pharmaceuticals LP | $13.24 | 2020 | |
| Almatica Pharma LLC | $11.84 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Haasis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.